Stoke Therapeutics, Inc. (STOK) Form 8-K — Oct 29, 2026
Stoke Therapeutics reported Q3 2026 results with a net loss of $73.6 million ($1.08/share) versus a $38.3 million loss a year ago, driven by R&D spending of $59.8 million supporting the Phase 3 EMPEROR study of zorevunersen. Nine-month revenue fell to $26.8 million from $183.0 million due to the prior-year $150.8 million Biogen license recognition. The Phase 3 EMPEROR study in Dravet syndrome is fully enrolled with 162 patients; ~110 are through the Week 28 primary endpoint and ~20 through Week 52, with no discontinuations. A data readout is anticipated in Q3 2027, followed by a planned U.S.
Key figures
- Revenue
- 11255000
- Total Assets
- 406692000
- Cash Position
- 358800000
- Cash runway
- into early 2028
- Q3 2025 revenue
- 10632000
- Q3 2025 net loss
- 38347000
- Ytd 2025 revenue
- 183018000
- Ytd 2026 revenue
- 26808000
- Ytd 2026 net loss
- 185265000
- Q3 r and d expense
- 59831000
- Shares outstanding
- 64813537
- Q3 sg and a expense
- 28739000
- Ndata readout timing
- Q3 2027
- Nda submission timing
- H2 2027
- Emperor enrolled patients
- 162
- Emperor patients through week 28
- ~110
- Emperor patients through week 52
- ~20
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.